Access all of the content
So pleased to have had an opportunity to catch-up with editorial board member, K Ray Chaudhuri (King’s Parkinson’s Centre, King’s College Hospital and Kings College London, UK), who shared his expert perspective on the clinical impact of COVID-19 on people with Parkinson’s disease.
1. What treatment strategies should be implemented in patients with Parkinson’s disease (PD) and pneumonia or upper respiratory tract infections resulting from COVID-19? (0:05)
2. What potential drug–drug interactions may occur between PD medications and drugs used to treat symptoms of COVID-19? (2:06)
3. What are the consequences of anxiety and prolonged immobility due to the lockdown on patients with PD? (2:49)
4. What other advice would you like to impart to healthcare professionals regarding patient management at this time? (4:39)
Also see linked video: K Ray Chaudhuri, EAN 2020 – Clinical Impact of COVID-19 on People With Parkinson’s Disease
Speaker disclosure: K Ray Chaudhuri has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!